AKT2 expression is associated with glioma malignant progression and required for cell survival and invasion

JUNXIA ZHANG1, LEI HAN1, ANLING ZHANG1, YINGYI WANG2, XIAO YUE2, YONGPING YOU2, PEIYU PU1 and CHUNSHENG KANG1

1Department of Neurosurgery, Tianjin Medical University General Hospital and Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin 300052; 2Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China

Received March 9, 2010; Accepted April 26, 2010
DOI: 10.3892/or_00000829

Abstract. Recent data suggest that AKT2, one of AKT isoforms, plays an important role in tumorigenesis of human cancers. However, little evidence exists to show the mechanism of AKT2 involved in tumorigenesis. In this study, we show that AKT2 protein expression increased significantly in high grade gliomas in comparison to low grade gliomas and correlated with the expression of NFκB, BCL2, MMP2 and MMP9 by immunostaining. Further, down-regulation of AKT2 expression by antisense AKT2 induced glioma cell apoptosis mediated by NFκB and BCL2. In addition, decreased MMP2 and MMP9 expression in AKT2 knocked-down glioma cells was subsequently detected, consistent with the decreased invasion. These findings indicate that AKT2 expression is associated with more advanced and especially aggressive gliomas and critical for cell survival and invasion.

Introduction

Gliomas, are the most frequent primary tumors that arise in the brain. The most malignant form of glioma, glioblastoma multiforme (Grade IV), is one of the most aggressive human cancers, with a median survival of less than 1 year. Despite recent advances in cancer treatment, this statistic has not changed significantly over the past years. Therefore, it is essential to investigate the mechanism involved in the development and progression of glioma.

Accumulating evidence has demonstrated that PI3K/AKT pathway is one of the important signaling pathways regulating various cellular biological processes, including growth, proliferation, survival, metabolism and motility. AKT, or protein kinase B, a serine/threonine kinase, is composed of three isoforms, AKT1, AKT2 and AKT3. Three isoforms of AKT are structurally homologous and share similar mechanisms of activation, but they also exhibit distinct features and roles (1). AKT1 and AKT2 are widely expressed, whereas AKT3 has restricted expression. Among three isoforms of AKT, AKT2 has been shown to be primarily involved in human cancer and play a central role in tumorigenesis. High expression of AKT2 has been detected in a variety of human cancers, such as laryngeal squamous cell carcinoma, breast cancer and ovarian cancer (2-4). However, there are some reports on the elevated expression of AKT2 in human gliomas (5,6), the relationship between AKT2 expression and glioma grade and the mechanism of AKT2 in gliomagenesis is still not clear.

In the current study, we examined whether AKT2 expression is associated with glioma malignant progression. AKT2 expression increased significantly with the increase in pathologic grade of gliomas and correlated positively with the expression of NFκB, BCL2, MMP2 and MMP9 by immunohistochemistry (IHC). Moreover, reduction of AKT2 by antisense AKT2 inhibited glioma cell survival by induction of apoptosis mediated by NFκB and BCL2. Additionally, down-regulation of AKT2 expression suppressed cell invasion via MMP2 and MMP9.

Materials and methods

Patients and samples. A glioma tissue microarray was obtained from Shanxi Chaoying Biotechnology (Xi’an, China). Pathologic grades of tumors were defined according to the 2000 WHO criteria as follows: 15 cases with Grade I, 15 cases with Grade II, 15 cases with Grade III, 15 cases with Grade IV. The array dot diameter was 1.5 mm and each dot represented a tissue spot from one individual specimen that was selected and pathologically confirmed. All microarrays were stored at 4°C without light.

Immunohistochemical analysis. Immunostaining was performed on 6 μm paraffin sections of tumor specimens by the avidin-biotin-complex (ABC) method as previously...
described (27). Briefly, the sections were incubated with primary antibody (1:100 dilution,) overnight at 4°C, then incubated with a biotinylated secondary antibody (1:200 dilution) at room temperature for 1 h, followed by the incubation with ABC-peroxidase reagent (1:200 dilution, Vector, USA) for an additional 1 h. After washing with Tris-buffer, the sections were stained with DAB (3,3 diaminobenzidine, 30 mg dissolved in 100 ml Tris-buffer containing 0.03% H2O2) for 5 min, rinsed in water and counterstained with hematoxylin. The antibodies used in this study were: antibodies to AKT2, NfXb, BCL2, MMP2, MMP9 (Santa Cruz, USA). Negative controls were obtained by substituting primary antibodies with non-immune serum. Sections with no labeling or with <5% labeled cells were scored as 0. Sections were scored as a 1 with labeling of 5-30% of cells, as a 2 with 31-70% of cells and as a 3 with labeling of ≥71%. The staining intensity was scored similarly, with 0 used for negative staining, 1 for weakly positive, 2 for moderately positive and 3 for strongly positive. The scores for the percentage of positive tumor cells and for the staining intensity were added to generate an immunoreactive score for each specimen. The product of the quantity and intensity scores were calculated such that a final score of 0-1 indicated negative expression (-), 2-3 indicated weak expression (+), 4-5 indicated moderate expression (++) and 6 indicated strong expression (+++). Each sample was examined separately and scored by two pathologists. Cases with discrepancies in the scores were discussed to reach a consensus.

Cell culture and transfection. Human glioblastoma cell lines (U251, LN229, SNB19) were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Science, Shanghai, China. Human glioblastoma cell line (T9305) was established in our laboratory (7). The cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine serum, and incubated at 37°C with 5% CO2. Plasmids pLXSN-AS-AKT2 were kindly provided by Dr Jinquan Cheng (University of South Florida, USA). pLXSN-AS-AKT2 was constructed by subcloning of a 1.2-kb fragment of a human AKT2 cDNA clone into an LXSN retroviral vector in the antisense orientation and the fragment was generated by deleting 70 amino acid residues from the C-terminus of the open reading frame of AKT2. Total protein lysates (40 μg/sample), were separated by SDS-PAGE. The separate proteins were transferred to PVDF membranes. The blot was incubated with primary antibody (AKT2, NfXB, BCL2, MMP2, MMP9), followed by incubation with HRP-conjugated secondary antibody. The specific protein was detected using a super signal protein detection kit (Pierce, USA). After washing with stripping buffer, the PVDF membrane was reprobed with antibody against GAPDH (Santa Cruz, USA).

Cell viability assay. Cells were seeded into 96-well plates at 4000 cells/well. Forty-eight hours after transfection, 20 μl of MTT (5 g/l) was added into each well and incubated for 4 h, and then the supernatant was discarded, for 5 consecutive days after treatment. Finally, 200 μl of DMSO was added to each well to dissolve the precipitate. Optical density (OD) was measured at the wavelength of 490 nm. The data were presented as the mean ± SD, derived from triplicate samples of three independent experiments.

Apoptosis assays. Transfected cells were harvestd and then analyzed for the apoptosis ratio using Annexin V FITC Apoptosis Detection kit (Becton-Dickinson, USA) according to the manufacturer’s instructions. Annexin V FITC and propidium iodide (PI) double stain was used to evaluate the percentages of apoptosis. Annexin V- and PI- cells were used as controls. Annexin V+ and PI+ cells were designated as apoptotic and Annexin V+ and PI- cells displayed necrotic. Tests were repeated in triplicate.

In vitro transwell invasion assays. Transwell membranes coated with matrigel (Becton-Dickinson) were used to assay invasion of glioma cells in vitro. Transfected cells were plated at 5x10^4 per well in the upper chamber in serum-free medium. PBS (20%) was added to the medium in the lower chamber. After incubating for 24 h, non-invading cells were removed from the top well with a cotton swab while the bottom cells were fixed in 95% ethanol and stained with hematoxylin, and photographed in three independent x400 fields for each well. Three independent experiments were done and used to calculate fold migration relative to blank control.

In vitro invasive growth assays on matrigel matrix. Transfected cells were seeded into duplicate 24-wells (10000 cells/well) pre-coated with 250 ml matrigel basement membrane matrix (Becton-Dickinson). After incubation for 36 h photographs were taken at x400 magnification by a light microscope.

Subcutaneous tumor assay. BALB/c-A nude mice at 6 weeks of age were purchased from animal center of the Cancer Institute of Chinese Academy of Medical Science. All experimental procedures were carried out according to the regulations and internal biosafety and bioethics guidelines of Tianjin Medical University and the Tianjin Municipal Science and Technology Commission. U251 glioma subcutaneous model was established as previously described (8). When the subcutaneous tumor reached 50 mm^3 in size, the mice were randomly divided into 3 groups (10 subcutaneous tumors/group). AS-AKT2 group: 10 μg pLXSN-AS-AKT2 and 10 μl lipofectamine were injected into the xenograft tumor model in a multi-site injection manner. Negative control group: 10 μg pLXSN and 10 μl lipofectamine were injected into the xenograft tumor model in a multi-site injection manner. Black control group: 10 μl PBS was injected into the
xenograft tumor model in a multi-site injection manner. Treatment was conducted at 2-day intervals, twice. The tumor volume was measured with a caliper every 4 days, using the formula volume = length x width^2/2 (9). At the end of 28-day observation period, the mice bearing xenograft tumors were sacrificed and the tumor tissues were removed for formalin fixation and preparation of paraffin-embedded sections for immunohistochemical analysis.

Statistical analysis. Data were analyzed with SPSS 10.0. ANOVA, t-test, \( \chi^2 \) test and the Pearson's correlation were used to analyze the significance between groups. Statistical significance was assigned to P-values < 0.05.

Results

AKT2 expression and its association with pathologic grade in gliomas. Immunostaining analysis revealed AKT2 protein was expressed in gliomas and its total positive rate was 78.3% (43/60). The levels of AKT2 protein increased markedly in high grade gliomas (WHO Grade III and IV) in comparison to low grade gliomas (WHO Grade I and II). Indeed, 27/30 high grade gliomas exhibited detectable levels of AKT2, while 16/30 low grade gliomas exhibited undetectable levels of the protein (P < 0.05) (Fig. 1). Additionally, there were no significant differences between AKT2 protein expression in the Grade III gliomas and that in the Grade IV gliomas.

In order to explore the relationship between AKT2 and survival and invasion markers in gliomas, NFκB, BCL2, MMP2 and MMP9 expression was evaluated. NFκB, BCL2, MMP2 and MMP9 expression increased significantly in high grade gliomas compared with low grade gliomas. Representative images of NFκB, BCL2, MMP2 and MMP9 immunostaining are shown in Fig. 1. The Pearson correlation showed that a significant positive correlation existed between AKT2 expression and NFκB and BCL2 expression (R = 0.7298, P < 0.0001 and R = 0.7857, P < 0.0001, respectively). A direct correlation between MMP2 and MMP9 expression and AKT2 expression was also observed (R = 0.6442, P < 0.0001 and R = 0.6887, P < 0.0001, respectively) (Fig. 2).

Reduction of AKT2 inhibits glioma cell survival. As shown in Fig. 3A, AKT2 expression in U251 cells was higher than that in other glioma cell lines. Therefore, we chose U251 cells
for further studies. In order to efficiently knock down AKT2 expression in glioma cells, antisense AKT2 expression plasmids were transfected into U251 cells. Western blot analysis showed antisense AKT2 induced a marked decrease in the protein levels for the target protein in U251 cells, with minimal effect on the expression of GAPDH, whereas negative plasmid left the AKT2 protein level unchanged (Fig. 3B). These results indicated that antisense AKT2 potently and specifically down-regulated AKT2 expression in glioma cells.

To evaluate the impact of down-regulation of AKT2 expression on glioma cell survival in vitro, MTT assay was employed. Fig. 3C shows that statistically significant cell proliferation inhibition of U251 cells was found in AS-AKT2 group compared with control groups on day 3. There was no difference between negative control group and blank control group in the whole experiment. Additionally, 3 days after transfection, the apoptosis ratio was measured by Annexin V and PI double stain. Significantly more apoptotic cells were detected in AS-AKT2 group, but no statistical difference of the levels of apoptosis was found in control groups (Fig. 3D). The results indicated that AKT2 appeared to depress glioma cell survival via induction of apoptosis.

Reduction of AKT2 inhibits glioma cell invasion. To investigate whether down-regulation of AKT2 expression could affect invasive ability of glioma cells, in vitro transwell invasion assay was employed. Invasive cells in AS-AKT2 group had the potential to digest the matrigel and migrate through the pores in the membrane. As shown in Fig. 4A, cells in AS-AKT2 group showed an average slightly >50% defective in migrating through matrigel compared with cells in control groups. Cells with invasive potential exhibit enhanced invasive growth on basement membranes such as matrigel matrix (10). We therefore assayed cell invasive growth on this type of semi-solid surface to measure changes in response to down-regulation of AKT2 expression by antisense AKT2. The majority of cells in control groups was completely adherent 12 h after seeding, and displayed robust cell growth 24 h after seeding. While down-regulation of AKT2 expression caused a substantial reduction of cell growth on matrigel in AS-AKT2 group (Fig. 4B). The results suggested that AKT2 is required for glioma cell invasion.

Gene regulation of antisense AKT2 at the protein level in vitro. In order to further explore the molecular mechanism of AKT2 in glioma cell survival and invasion, Western blot analysis was used. NFκB, BCL2, MMP2 and MMP9 are important downstream molecules of Akt signaling pathway involved in cell survival and invasion. As shown in Fig. 5, an obvious inactivation of NFκB and BCL2 was observed in U251 after transfection. Consistently, down-regulation of AKT2
expression led to a marked reduction of MMP2 and MMP9 protein expression.

Reduction of AKT2 inhibits glioma growth in vivo. To explore the effect of AKT2 on tumor growth in vivo, we implied a xenograft glioma mouse model. On day 12, the tumors of AS-AKT2 group started to reach statistical significance compared with control groups (P<0.05). At the termi-
nation of the study, the difference in tumor mass between AS-AKT2 group and control groups was marked (P<0.01). As shown in Fig. 6A and B, the tumor volumes on day 28 were 2392±633 mm$^3$, 6263±2637 mm$^3$ and 7132±2835 mm$^3$ in the AS-AKT2 group, negative control group and blank control group, respectively.

After mice were observed for 28 days, the tumor samples were taken, and paraffin-embedded section was prepared for immunohistopathological examination. Similar to the results obtained from the in vitro study, the expression of AKT2, NF$\kappa$B, BCL2, MMP2 and MMP9 in tumor specimens of AS-AKT2 group was prominently down-regulated (Fig. 6C). Cell apoptosis in tumor samples was examined by the TUNEL method, which showed that the number of apoptotic cells was dramatically increased in the tumors from AS-AKT2 treated mice when compared with those in tumors from the control mice.

Discussion

Cancer cells escape normal growth control mechanisms as a consequence of activating (i.e., gain-of-function) mutations and/or increased expression of one or more cellular proto-oncogenes and/or inactivating (i.e., loss-of-function) mutations and/or decreased expression of one or more tumor suppressor genes (11). Most oncogene and tumor suppressor gene products are components of signal transduction pathways that control cell cycle entry or exit, promote differentiation, sense DNA damage and initiate repair mechanisms, and/or regulate cell death programs. AKT pathway is the most widely studied component of the pathway networks due to its involvement in cell survival, migration and invasion. In this study, our results revealed that AKT2, one of AKT isoforms, was associated with glioma grade and critical for glioma cell survival and invasion.

Up to date the expression pattern and function of the different AKT isoforms in human tumors are not completely elucidated. It has been shown that AKT1 and AKT2 are ubiquitously expressed in all tissue types so far examined (12), while AKT3 is predominantly expressed in testis and neuronal tissue and is up-regulated in some transformed cells such as in hormone-independent breast and prostate cancer cell lines (13,14). Bellacosa and colleagues found an amplification of AKT2 was associated with undifferentiated carcinomas and poor prognosis (15). Elevated activity levels of AKT2, were associated with high-grade and high-stage ovarian carcinomas (16). Despite high expression of AKT2 in glioma, the relationship between AKT2 expression and tumor grade is still unknown. In our study, AKT2 expression detected by immunohistochemistry and Western blot analysis
increased significantly with the increase in glioma grade according to the WHO classification. Additionally, AKT2 expression significantly correlated with the antiapoptotic and invasive potential of gliomas, as evaluated by the NFkB, BCL2, MMP2 and MMP9 expression. These results suggest that AKT2 expression is associated with more advanced and especially aggressive gliomas.

Recent reports have shown that the relative importance of the AKT isoforms in cell survival is cell line-specific (17). In human breast cancer ZR-75 cells, AKT1 is the predominant isoform responsible for cell survival. Conversely, in human ovarian carcinoma IGROV1 cells, no single isoform is essential for cell survival. Tumor necrosis factor-like inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival. Depletion of AKT2 expression by siRNA abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival is observed after siRNA-mediated depletion of AKT1 expression (18). Our data suggested that down-regulation of AKT2 expression by antisense AKT2 significantly inhibited glioma cell survival through induction of apoptosis mediated by activation of NFkB and BCL2. As far as we know, in a cell-free apoptosis system, mitochondria spontaneously release cytochrome c, leading to apoptotic nuclear morphology. Cytochrome c interacts with Apaf-1, leads to the activation of caspases and finally results in apoptosis. Previous studies have identified that AKT pathway regulates cell apoptosis by inactivation of NFkB and BCL2. NFkB, plays an important role in the regulation of apoptotic cell death via protecting from various apoptotic stimuli in different cellular systems (19). BCL2, which acts to prevent the release of cytochrome c and caspase activation, is a potent inhibitor of apoptotic cell death (20). These results provide sufficient evidence for the importance of the role of down-regulation of NFkB and BCL2 in antisense AKT2-induced apoptosis.

High levels of MMP2 and MMP9 in tissues are associated with tumor cell invasion (21). MMP2 and MMP9 are thought to be key enzymes involved in the degradation of type IV collagen, which is a component of the extracellular matrix. Additionally, the AKT pathways have been documented to play a critical role in the regulation of cell proliferation and survival (22). In glioma cells, AKT2 contributes to glioma cell migration and invasion by regulating the formation of cytoskeleton, influencing adhesion and increasing expression of MMP9 (6). In this study, decreased invasive activity was observed in glioma cells by treatment with antisense AKT2. It prompted us to survey its relationship to expression of invasion-associated proteins. Significant difference in decreased MMP2 and MMP9 expression was observed in AS-AKT2 group versus blank control or silencing control (22,23). In glioma cells, AKT2 contributes to cell migration through MMP2 and MMP9 suppression. Moreover, down-regulation of AKT2 expression by antisense AKT2 inhibited glioma cell survival by induction of apoptosis mediated by NFkB and BCL2. Additionally, down-regulation of AKT2 expression induced invasion suppression via MMP2 and MMP9. Therefore, down-regulation of AKT2 expression may offer potential opportunities for glioma gene therapy.

Acknowledgements

Supported by China National Natural Scientific Foundation (30971136), Program for New Century Excellent Talents in University (NCET-07-0615) and Natural Science Foundation of Tianjin Municipal Science and Technology Commission (09JZCDJC17600).

References


